Bionor Pharma ASA – Number of subscription rights per share in the conditional Subsequent Offering
Oslo, 30 November 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANYOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.
Reference is made to Bionor Pharma ASA's (“Bionor” or the “Company”) announcement regarding the key information relating to the conditional subsequent offering (the“Subsequent Offering”) published 24 November 2016. The Subsequent Offering is inter alia subject to approval by the extraordinary general meeting (the “EGM”) to be held on 14 December 2016, completion of the Company's acquisition of Solon Eiendom AS and the Private Placement and a prospectus being approved by the Norwegian Financial Supervisory Authority and published by the Company.
Existing shareholders who were not allocated shares in the Private Placement nor participated in the underwriting consortium, provided that such shareholders are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action, are eligible to participate in the Subsequent Offering (“Eligible Shareholders”).
Eligible Shareholders will receive approximately 0.65 subscription rights per existing shares in Bionor held as of 25 November 2016. One subscription right will give the right to subscribe and be allocated one new Bionor share in the Subsequent Offering.
Fractions of subscription rights will not be allotted and issued and all fractional entitlements will be rounded down to the nearest whole number of subscription rights. Fractional entitlements of subscription rights will not be paid, nor will they be aggregated and sold in the market.
The subscription period for the Subsequent Offering will commence after approval of a prospectus by the Norwegian Financial Supervisory Authority which is expected in the first half of January 2017.
The Company will provide additional information about the Subsequent Offering in due course.
Einar J. Greve, Chairman of the Board, Bionor Pharma ASA
E-mail: email@example.comCell Phone: +47 900 27 766
Unni Hjelmaas Acting Chief Executive Officer, Bionor Pharma ASA
E-mail:firstname.lastname@example.org Cell Phone: +47 915 19 651
Announcement in pdf